Venus Remedies, a research-based global pharmaceutical company, has received another patent from Mexico for its novel antibiotic product potentox. Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of potentox.
The patent provides an exclusivity period for potentox up to 2025. The drug is also protected by a number of other patents from various other countries, including the US, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine. Potentox is an antibiotic adjuvant entity (AAE), a drug effective in case of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes.
Venus is upbeat about the response potentox has received in the domestic and global markets. “The product is growing at a compound annual growth rate (CAGR) of 50 per cent since the past three years. To take this novel antibiotic adjuvant entity to Mexico, the company is already holding talks with some big pharma companies there for strategic tie-ups. The common technical document (CTD) for Mexico is ready, and we will soon be filing it. But it will take us another two-three years to launch the product in this market,” said Dheeraj Aggarwal, Chief Financial Officer, Venus Remedies.
Terming such global recognitions for novel research products as a matter of pride for the research team at Venus, Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Medical Research Centre (VMRC), Venus Remedies, said, “It will motivate us to keep working hard to bring to the world our greatest research breakthroughs that would help in bridging the gaps in the field of emerging antimicrobial resistance.”
The global hospital-acquired bacterial infections market was estimated to be worth $9 billion in 2010. Potentox is designed to address the needs of almost 50 per cent of this market. The hospital-treated infections (HTI) market is projected to grow at a rate of 2.7 per cent annually in major economies.
EP News Bureau – Mumbai